Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology - United Kingdom
doi 10.1002/hon.123_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Rapid Relapse of Large B‐Cell Lymphoma After CD19 Directed CAR‐T‐Cell Therapy Due to CD‐19 Antigen Loss

American Journal of Hematology
Hematology
2019English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CAR T-Cell Therapy for Solid Tumors?

Cancer Discovery
Oncology
2018English

MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before Cd19 Car T Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Toxicities of CD19 CAR-T Cell Immunotherapy

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy